The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Official Title: A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer
Study ID: NCT01017731
Brief Summary: The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
Detailed Description: The primary purpose of this study is to determine if treatment with ramucirumab causes prolongation of the QTc/QT interval in participants with advanced cancer, to assess the safety and tolerability of ramucirumab therapy, and to evaluate the pharmacokinetic (PK) characteristics of ramucirumab
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
ImClone Investigational Site, Atlanta, Georgia, United States
ImClone Investigational Site, Metairie, Louisiana, United States
ImClone Investigational Site, Ann Arbor, Michigan, United States
ImClone Investigational Site, Philadelphia, Pennsylvania, United States
ImClone Investigational Site, Providence, Rhode Island, United States
ImClone Investigational Site, Houston, Texas, United States
ImClone Investigational Site, Seattle, Washington, United States
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR